Genetic testing in 2024 identified a heterozygous pathogenic ATM frameshift variant (c.4828dup, p.Arg1610Lysfs*3), confirming the diagnosis of ataxia–telangiectasia. This evidence concerns the gene ATM and ataxia telangiectasia.